Carbon Dioxide
Autonomic Dysfunction
University of Missouri-ColumbiaSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Autonomic Dysfunction cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
IVABRADINE Dana-Farber Cancer Institute | Phase 2 | CCC |
Baclofen University Hospital, Bordeaux | Phase 2 | CCC |
PROPRANOLOL Johns Hopkins University | Phase 1/2 | CCC |
Esmolol Johns Hopkins University | Phase 1/2 | CCC |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Jonathann Kuo, MD | Phase 1 | CC |
Gilenya Jochen Vehoff | Phase 4 | NR |
Same molecule, other indications
Carbon Dioxide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →